UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
--------
FORM 8-K
--------
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
September 24, 2007
Date of Report (Date of earliest event reported)
--------
PRO-PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
--------
NEVADA 000-32877 04-3562325
(State or Other Jurisdiction (Commission File Number) (IRS Employer
of Incorporation) Identification No.)
7 WELLS AVENUE
NEWTON, MASSACHUSETTS
02459
(Address of Principal Executive Offices) (Zip Code)
(617) 559-0033
(Registrant's telephone number, including area code)
--------
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
|_| Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
================================================================================
================================================================================
Change in Directors or Principal Officers, Financial Statements and Exhibits
Item 5.02. Departure of Directors or Principal Officers; Election of Directors:
Appointment of Principal Officers.
On September 24, Pro-Pharmaceuticals, Inc. ("the Company") announced that
Theodore H. Zucconi, Ph.D., has been named President, a position previously held
by David Platt, Ph.D., who will continue to serve as Chief Executive Officer and
Chairman of the Board of Directors. Dr. Zucconi also has been nominated to serve
on the Company's Board of Directors.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
News Release of Pro-Pharmaceuticals, Inc., dated September 24, 2007.
================================================================================
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
PRO-PHARMACEUTICALS, INC.
By: /s/ David Platt
------------------------
David Platt
Chief Executive Officer
Date: September 24, 2007
================================================================================
EXHIBIT INDEX
Exhibit
Number Exhibit
----------- --------------------------------------------------------------------
99.1 News Release of Pro-Pharmaceuticals, Inc., dated September 24, 2007.